Go Pro
NASDAQ:QCLS

Mymd Pharmaceuticals Q1 2026 Earnings Report

Mymd Pharmaceuticals logo
$2.41 -0.17 (-6.59%)
Closing price 08/24/2026 04:00 PM Eastern
Extended Trading
$2.44 +0.02 (+1.04%)
As of 08/24/2026 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mymd Pharmaceuticals EPS Results

Actual EPS
-$0.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mymd Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mymd Pharmaceuticals Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Friday, May 15, 2026
Conference Call Time
7:00AM ET

Earnings Documents

Mymd Pharmaceuticals Earnings Headlines

The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
See More Mymd Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mymd Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mymd Pharmaceuticals and other key companies, straight to your email.

About Mymd Pharmaceuticals

Mymd Pharmaceuticals (NASDAQ:QCLS) is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation. MyMD Pharmaceuticals is based in the United States and has operated as a research-driven biotechnology company centered on bringing new therapeutic options to market.

Because company details can change over time and reliable, up-to-date information on leadership and current geographic operations is limited, this description is intentionally brief and limited to broadly verifiable business information.

View Mymd Pharmaceuticals Profile